Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children
Open Access
- 2 September 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (9) , e105110
Abstract
Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. Patients aged ≤18 years documented in the Bavarian Association of Statutory Health Insurance Physicians database (approx. 2 million children) between 2004 and 2008 were included in our study. Annual period prevalence rates (PPRs) per 10,000 children and the proportion of age- and indication-related off-label prescriptions were calculated and stratified by age and gender. Within the study period, highest PPRs were found for the fixed combination of clenbuterol/ambroxol (between 374–575 per 10,000 children) and the inhaled short acting beta-2-agonist salbutamol (between 378–527 per 10,000 children). Highest relative PPR increase was found for oral salbutamol (approx. 39-fold) whereas the most distinct decrease was found for oral long-acting beta-2-agonist clenbuterol (−97%). Compound classes most frequently involved in off-label prescribing were inhaled bronchodilative compounds (91,402; 37.3%) and oral beta-2-agonists (26,850; 22.5%). The highest absolute number of off-label prescriptions were found for inhaled salbutamol (n = 67,084; 42.0%) and oral clenbuterol/ambroxol (fixed combination, n = 18,897; 20.7%). Off-label prescribing due to indication was of much greater relevance than age-related off-label use. Most frequently, bronchodilative compounds were used off-label to treat respiratory tract infections. Highest off-label prescription rates were found in the youngest patients without relevant gender-related differences. Off-label prescribing of respiratory drugs is common especially in young children. Bronchodilative drugs were most frequently used off-label for treating acute bronchitis or upper respiratory tract infections underlining the essential need for a more rational prescribing in this area.Keywords
This publication has 22 references indexed in Scilit:
- Rational prescribing is important in all settingsArchives of Disease in Childhood, 2013
- Bronchodilators for bronchiolitis2010
- Association between licence status and medication errorsArchives of Disease in Childhood, 2010
- Assessment of Pediatric asthma drug use in three European countries; a TEDDY studyEuropean Journal of Pediatrics, 2010
- In‐label and off‐label use of respiratory drugs in the Italian paediatric populationActa Paediatrica, 2010
- Asthma Therapy During the First 8 Years of Life: A PIAMA Cohort StudyJournal of Asthma, 2010
- Therapeutic approach to bronchiolitis: why pediatricians continue to overprescribe drugs?Italian Journal of Pediatrics, 2010
- Management of acute bronchiolitis: can evidence based guidelines alter clinical practice?Thorax, 2008
- Prescription of respiratory medication without an asthma diagnosis in children: a population based studyBMC Health Services Research, 2008
- The Impact of Unlicensed and Off-Label Drug Use on Adverse Drug Reactions in Paediatric PatientsDrug Safety, 2004